OncRef

Clinical Trial: NCT06671379

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Information Provided By:Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Last Update Posted:2026-03-19

Study Overview

Brief Summary

This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.

Official Title

A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: SHR-A2009 monotherapy
  • Drug: platinum-based dual-agent chemotherapy

Other Study ID Numbers

  • SHR-A2009-301

Start Date (Actual)

2024-11-29

Primary Completion Date (Estimated)

2026-12

Study Completion Date (Estimated)

2027-06

Enrollment (Actual)

498

Study Type

Interventional

Phase

Phase 3